Benjamin Meadows, serving as the Chief Commercial Officer for Quanterix Corp (NASDAQ:QTRX), has completed a transaction to acquire shares of the company. This activity was documented in a Form 4 filing lodged with the Securities and Exchange Commission.
The transaction took place on May 12, 2026. Mr. Meadows acquired 3,500 shares of Quanterix common stock. The shares were bought at a price of $2.77 per share. This resulted in a total transaction value of $9,695. Following this purchase, Mr. Meadows holds a direct position of 3,500 shares of Quanterix common stock.
The stock acquisition occurs while the shares have experienced a decline of approximately 60% over the previous six-month period. As of the reporting date, the stock was trading at $3.10. The company's market capitalization stands at $146.5 million. Analysis from InvestingPro suggests that the stock may be undervalued relative to its Fair Value assessment. Investors looking for additional data can review eight further InvestingPro Tips for QTRX, which include evaluations of the company's cash position and its profitability outlook.
In recent corporate developments, Quanterix Corporation reported its first-quarter earnings for 2026. The company posted an earnings per share of -$0.37. This result exceeded analyst expectations, which were set at -$0.47. Despite this positive earnings surprise, the company reported a revenue shortfall. Revenue was recorded at $36.4 million, falling short of the anticipated $37.22 million.
Quanterix also announced leadership changes. Jason Faessler has been appointed as the new chief financial officer, effective June 22. Prior to this role, Faessler served as a senior vice president at Bruker Corporation, where he directed global financial planning and analysis. Vandana Sriram, the current CFO, is scheduled to depart on June 15, 2026. The company is currently searching for her successor.
Another leadership adjustment involves Geoff Albrecht, who has been appointed as Senior Vice President and General Manager of Diagnostics. Albrecht will focus on the company's diagnostics strategy, with a specific emphasis on Alzheimer's Disease diagnostics. These moves reflect Quanterix's ongoing efforts to strengthen its leadership team and refine its strategic focus.